Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial
Authors' conclusion
In these post hoc analyses, in participants with obesity or overweight, tirzepatide was associated with reduced blood pressure consistently across participant groups primarily via weight loss, with relatively few blood pressure-related adverse events.
Study context
- Population
- People with obesity or overweight with weight-related complications
- Comparison
- Tirzepatide vs placebo
- Primary endpoint
- Change in SBP and DBP, overall and across subgroups
- Follow-up
- 72 weeks
Methodological detailsstratified subgroup analyses, mediation analysis
- Stratified subgroup analyses
- Mediation analysis
Primary result
As reported in the abstract
Net BP reduction vs placebo
Net reduction
6.8 mm Hg
SBP; significant
Net reduction
4.2 mm Hg
DBP; significant
Further findings
Normal BP · week 72 · any tirzepatide group
Proportion of BP reduction explained by weight loss (mediation analysis)
- SBP reduction explained by weight loss
- 68%
- DBP reduction explained by weight loss
- 71%
Safety
Low BP adverse events
- Infrequent, but rate higher with tirzepatide
Original publication
Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial. Heart. Published 31 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →